Impact of COVID-19 outbreak in an Italian cohort of patients with systemic sclerosis.

Nicoletta Del PapaGianluca SambataroAntonina MinnitiWanda MaglioneFrancesca PignataroAntonella CaminatiSergio HarariDomenico SambataroClaudio VitaliRoberto Felice Caporali

Published in: Therapeutic advances in musculoskeletal disease (2020)

Despite the large prevalence of ILD and immunosuppressive therapies, which can be considered risk factors for the occurrence and severity of incidental viral infections, the impact of COVID-19, in terms of mortality rate and morbidity, does not appear particularly severe in this large cohort of patients with SSc. Possible mechanisms influencing this figure are discussed.

Keyphrases

systemic sclerosis
interstitial lung disease
sars cov
risk factors
coronavirus disease
risk assessment
rheumatoid arthritis
idiopathic pulmonary fibrosis
cardiovascular events
early onset
respiratory syndrome coronavirus